AML1 complex as a molecular target for leukemia therapy

AML1复合物作为白血病治疗的分子靶点

基本信息

  • 批准号:
    15390033
  • 负责人:
  • 金额:
    $ 9.41万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2005
  • 项目状态:
    已结题

项目摘要

The genes encoding the AML1/CBFβ transcription factor complex are the most frequent targets of chromosome translocations found in human leukemia. We previously purified AML1 complexes, and found that the complex contains histone acetyltransferases such as p300 and MOZ, promyelocytic leukemia isoform I (PML I), and a protein kinase (HIPK2). The genes encoding AML1 and some of the AML1-interacting proteins are the targets of leukemia-associated chromosome translocations, suggesting that common pathways may be shared by distinct myeloid malignancies and underscores the importance of this complex in hematopoiesis and leukemogenesis. HIPK2 formed a complex with AML1 and p300, and phosphorylated both AML1 and p300 to stimulate both transcription activation and HAT activities. Phosphorylation of p300 was triggered by phosphorylated AML1 as well as by PU.1, c-MYB, c-JUN, and c-FOS, and was inhibited by dominant-negative HIPK2. Phosphorylation of p300 and AML1 was impaired in Hipk1/2 double-def … More icient mouse embryos. Double-deficient mice exhibited defects in primitive/definitive hematopoiesis, vasculogenesis, angiogenesis and neural tube closure. These phenotypes are in part similar to those observed in p300- and CBP-deficient mice. HIPK2 also phosphorylates another co-activator, MOZ, in an AML1-dependent manner. These results suggest a novel mechanism by which transcription factors could regulate local histone acetylation and transcription of their target genes. To investigate the roles of MOZ in normal hematopoiesis, we generated MOZ-null mice. MOZ^<-/-> mice died around E15. In MOZ^<-/-> E14.5 embryos, hematopoietic stem cells, lineage-committed progenitors and B lineage cells were severely reduced. On the other hand, arrest of erythroid maturation and elevated myeloid lineage populations were observed. MOZ-deficient fetal liver cells could not reconstitute hematopoiesis of recipients after transplantation. Analysis using microarray and flow cytometry revealed that expression of thrombopoietin receptor (c-Mpl), HoxA9 and c-Kit was down-regulated. These results show that MOZ is required for maintenance of hematopoietic stem cells and that it plays a role in differentiation of erythroid and myeloid cells. Less
编码AML1/CBFβ转录的基因是人类白血病中发现的最常见的染色体易位。 . The Genes Encoding AML1 AML1-Interacting Proteins Is The Targets of Leukemia-Associated Crumosome Slocations, Surgesting that Common Pathways May Be Shared by Distinct Myeloid MalignNCIES AND UNDERSCORES THE IMPORTANCE OF THIS COMPLEX in Hematopoiesis and Leukemogenesis. Ctivation and Hat Activities. Phosphorylation of P300由磷酸化的AML1以及PU.1,C-Myb,C-Jun和C-Fos触发,并在HIPK1/2双DEF中受到了p300和AML1的抑制。 ..胚胎中的双重缺陷小鼠在原始 /确定的造血,血管生成,血管生成和神经管闭合部分 - 这些结果表明,转录因子可以局部组成,我们的靶代蛋白会产生moz-Z-null小鼠E14.5胚胎,造血干细胞,谱系的祖细胞和B谱系细胞被降低。这些结果表明,维持造血干细胞需要MOZ,并且在分化红细胞和髓样细胞中起作用

项目成果

期刊论文数量(30)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mutations and deletions of the CBP gene in human lung cancer.
MLL forms f SETI-like histone methyltransferase complex with menin to regulate Hox gene expression.
MLL 与 menin 形成 f SETI 样组蛋白甲基转移酶复合物来调节 Hox 基因表达。
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yokoyama A.;Wang Z.;Wysocka J.;Sanyal M.;Aufiero DJ.;Kitabayashi I.;Herr W.;Cleary
  • 通讯作者:
    Cleary
Physical and functional link of the leukemia-associated factors AMLI and PML.
白血病相关因子 AMLI 和 PML 的物理和功能联系。
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Nguyen LA.;Pandolfi PP.;Aikawa Y.;Tagata Y.;Ohki M.;Kitabayashi I.
  • 通讯作者:
    Kitabayashi I.
Nemo-like kinase suppresses a wide range of transcription factors, including nuclear factor-kappaB.
Nemo 样激酶可抑制多种转录因子,包括核因子 -kappaB。
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yasuda J;Yokoo H;Yamada T;Kitabayashi I;Sekiya T;Ichikawa H.
  • 通讯作者:
    Ichikawa H.
Yasuda J, Yokoo H, Yamada T, Kitabayashi I, Sekiya T, Ichikawa H.: "Nemo-like kinase suppresses a wide range of transcription factors, including nclear factor-kappaB."Cancer Sci.. 95. 52-57 (2004)
Yasuda J、Yokoo H、Yamada T、Kitabayashi I、Sekiya T、Ichikawa H.:“Nemo 样激酶抑制多种转录因子,包括核因子-kappaB。”Cancer Sci.. 95. 52-57 (2004
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KITABAYASHI Issay其他文献

KITABAYASHI Issay的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KITABAYASHI Issay', 18)}}的其他基金

Development of the novel AML treatments by targeting leukemia stem cells
开发针对白血病干细胞的新型 AML 治疗方法
  • 批准号:
    22390197
  • 财政年份:
    2010
  • 资助金额:
    $ 9.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Study for regulatory mechanism of normal and leukemic stem cells through transcription factors
转录因子对正常和白血病干细胞的调控机制研究
  • 批准号:
    19390268
  • 财政年份:
    2007
  • 资助金额:
    $ 9.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional study of leukemia-associated factor AML1
白血病相关因子AML1的功能研究
  • 批准号:
    17013091
  • 财政年份:
    2005
  • 资助金额:
    $ 9.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas

相似国自然基金

选择性靶向MOZ的小分子:设计合成及其抗MOZ融合相关急性髓系白血病活性研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    24 万元
  • 项目类别:
    青年科学基金项目
基于阿莫地喹为探针的AD中小胶质细胞TREM2表达调控机制研究
  • 批准号:
    81903588
  • 批准年份:
    2019
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
与辫子群有关的几个问题的研究
  • 批准号:
    11201449
  • 批准年份:
    2012
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Mechanisms of AF10-rearranged leukemia
AF10重排白血病的机制
  • 批准号:
    22H03109
  • 财政年份:
    2022
  • 资助金额:
    $ 9.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
熱力学量を正確に計算することを目指したOZ理論の改良
OZ 理论的改进旨在精确计算热力学量
  • 批准号:
    16K05659
  • 财政年份:
    2016
  • 资助金额:
    $ 9.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment the novel treatment strategy from the analysis of MLL gene rearranged refractory infantile leukemia
从MLL基因重排难治性婴儿白血病分析建立新的治疗策略
  • 批准号:
    15K19605
  • 财政年份:
    2015
  • 资助金额:
    $ 9.41万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
MOZ regulates cellular senescence
MOZ 调节细胞衰老
  • 批准号:
    nhmrc : 1084509
  • 财政年份:
    2015
  • 资助金额:
    $ 9.41万
  • 项目类别:
    Project Grants
The role of Moz, an epigenetic regulator, in the pathogenesis of leukaemia
表观遗传调节因子 Moz 在白血病发病机制中的作用
  • 批准号:
    nhmrc : 1030704
  • 财政年份:
    2012
  • 资助金额:
    $ 9.41万
  • 项目类别:
    Project Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了